| Nadia Carolina Azuero, MD | |
|
523 Windstone Trl, Alpharetta, GA 30004-5733 | |
| (404) 944-0685 | |
| Not Available |
| Full Name | Nadia Carolina Azuero |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 523 Windstone Trl, Alpharetta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528622677 | NPI | - | NPPES |
| 7100722380 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 55651 (Kentucky) | Primary |
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
Prof. Claudio Cuello at McGill University and his collaborators have genetically manipulated rats that can emulate Alzheimer's disease in humans, enabling research that will include the development of new treatments. Alzheimer's is a devastating brain condition leading to a progressive decline of memory and other brain functions. Although research mice have been developed in the past, rats are more intelligent than other rodents and the behavior of these rats is rich and predictable, which means that for the first time researchers will be able to detect and study the evolution of learning and memory deficits.
Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte Kuperwasser of Tufts University School of Medicine (TUSM) has determined that common forms of breast cancer originate from breast cells known as luminal epithelial cells while rarer forms of breast cancer, such as metaplastic carcinomas, originate from basal epithelial cell types.
Leading interventional cardiologists at The Mount Sinai Hospital are the first in the world to use a newly U.S. Food and Drug Administration approved device for the treatment of severely calcified coronary arteries before the placement of a cardiac stent to open a blocked artery.
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
› Verified 4 days ago
| Entity Name | South Central Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427611854 PECOS PAC ID: 6507195492 Enrollment ID: O20210126001625 |
News Archive
Prof. Claudio Cuello at McGill University and his collaborators have genetically manipulated rats that can emulate Alzheimer's disease in humans, enabling research that will include the development of new treatments. Alzheimer's is a devastating brain condition leading to a progressive decline of memory and other brain functions. Although research mice have been developed in the past, rats are more intelligent than other rodents and the behavior of these rats is rich and predictable, which means that for the first time researchers will be able to detect and study the evolution of learning and memory deficits.
Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte Kuperwasser of Tufts University School of Medicine (TUSM) has determined that common forms of breast cancer originate from breast cells known as luminal epithelial cells while rarer forms of breast cancer, such as metaplastic carcinomas, originate from basal epithelial cell types.
Leading interventional cardiologists at The Mount Sinai Hospital are the first in the world to use a newly U.S. Food and Drug Administration approved device for the treatment of severely calcified coronary arteries before the placement of a cardiac stent to open a blocked artery.
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
› Verified 4 days ago
| Entity Name | Baptist Health Deaconess Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437730942 PECOS PAC ID: 6103220330 Enrollment ID: O20210810000993 |
News Archive
Prof. Claudio Cuello at McGill University and his collaborators have genetically manipulated rats that can emulate Alzheimer's disease in humans, enabling research that will include the development of new treatments. Alzheimer's is a devastating brain condition leading to a progressive decline of memory and other brain functions. Although research mice have been developed in the past, rats are more intelligent than other rodents and the behavior of these rats is rich and predictable, which means that for the first time researchers will be able to detect and study the evolution of learning and memory deficits.
Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte Kuperwasser of Tufts University School of Medicine (TUSM) has determined that common forms of breast cancer originate from breast cells known as luminal epithelial cells while rarer forms of breast cancer, such as metaplastic carcinomas, originate from basal epithelial cell types.
Leading interventional cardiologists at The Mount Sinai Hospital are the first in the world to use a newly U.S. Food and Drug Administration approved device for the treatment of severely calcified coronary arteries before the placement of a cardiac stent to open a blocked artery.
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nadia Carolina Azuero, MD 523 Windstone Trl, Alpharetta, GA 30004-5733 Ph: (404) 944-0685 | Nadia Carolina Azuero, MD 523 Windstone Trl, Alpharetta, GA 30004-5733 Ph: (404) 944-0685 |
News Archive
Prof. Claudio Cuello at McGill University and his collaborators have genetically manipulated rats that can emulate Alzheimer's disease in humans, enabling research that will include the development of new treatments. Alzheimer's is a devastating brain condition leading to a progressive decline of memory and other brain functions. Although research mice have been developed in the past, rats are more intelligent than other rodents and the behavior of these rats is rich and predictable, which means that for the first time researchers will be able to detect and study the evolution of learning and memory deficits.
Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte Kuperwasser of Tufts University School of Medicine (TUSM) has determined that common forms of breast cancer originate from breast cells known as luminal epithelial cells while rarer forms of breast cancer, such as metaplastic carcinomas, originate from basal epithelial cell types.
Leading interventional cardiologists at The Mount Sinai Hospital are the first in the world to use a newly U.S. Food and Drug Administration approved device for the treatment of severely calcified coronary arteries before the placement of a cardiac stent to open a blocked artery.
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
› Verified 4 days ago
Elizabeth T Sergile, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 Old Milton Pkwy, Ste A130, Alpharetta, GA 30005 Phone: 770-664-8898 Fax: 770-772-4377 | |
Dr. Stuart Irwin Levin, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1040 Cambridge Sq, Suite E, Alpharetta, GA 30009 Phone: 770-569-2020 Fax: 770-569-5550 | |
Dr. Thomas E Reeths, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 5655 Atlanta Hwy Ste A, Alpharetta, GA 30004 Phone: 770-343-6364 | |
Dr. Satishkumar Mudduranganath Ganjam, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3905 Brookside Pkwy Ste 300, Alpharetta, GA 30022 Phone: 770-442-1911 Fax: 707-442-0306 | |
Mr. Pedro Antonio Ramirez, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 261 North Main Street, Alpharetta, GA 30004 Phone: 770-664-5660 Fax: 770-663-8672 | |
Dr. Mark James Sakr, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3400 Old Milton Pkwy Ste C190, Alpharetta, GA 30005 Phone: 855-647-7678 | |
Dr. Jignesh R Dholaria, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 260 Rucker Rd Ste 400, Alpharetta, GA 30004 Phone: 470-956-4540 Fax: 770-667-9783 |